| Primary |
| Cushing's Syndrome |
20.0% |
| Pituitary-dependent Cushing's Syndrome |
11.5% |
| Hypertension |
9.1% |
| Hypokalaemia |
9.1% |
| Ectopic Acth Syndrome |
4.2% |
| Gastritis |
4.2% |
| Hypothyroidism |
4.2% |
| Prophylaxis |
4.2% |
| Acth-producing Pituitary Tumour |
3.6% |
| Diabetes Mellitus |
3.6% |
| Hypercorticoidism |
3.6% |
| Infection Prophylaxis |
3.6% |
| Mental Disorder |
3.6% |
| Pneumonia |
3.6% |
| Nephrogenic Diabetes Insipidus |
3.0% |
| Adrenocortical Insufficiency Acute |
2.4% |
| Infection |
2.4% |
| Acth Stimulation Test |
1.2% |
| Gastric Ulcer |
1.2% |
| Hyperadrenocorticism |
1.2% |
|
| Respiratory Failure |
16.4% |
| Death |
8.2% |
| Nausea |
8.2% |
| Pneumocystis Jiroveci Pneumonia |
8.2% |
| White Blood Cell Count Increased |
6.6% |
| Drug Interaction Potentiation |
4.9% |
| Pyrexia |
4.9% |
| Septic Shock |
4.9% |
| Vomiting |
4.9% |
| Alanine Aminotransferase Increased |
3.3% |
| Fatigue |
3.3% |
| Mental Status Changes |
3.3% |
| Pituitary Tumour |
3.3% |
| Po2 Decreased |
3.3% |
| Potentiating Drug Interaction |
3.3% |
| Stupor |
3.3% |
| Surgery |
3.3% |
| Thrombocytopenia |
3.3% |
| Adrenal Carcinoma |
1.6% |
| Aspartate Aminotransferase Increased |
1.6% |
|
| Secondary |
| Hypercorticoidism |
19.9% |
| Hypertension |
15.6% |
| Pituitary-dependent Cushing's Syndrome |
13.4% |
| Cushing's Syndrome |
9.1% |
| Adrenocortical Insufficiency Acute |
7.5% |
| Hypokalaemia |
7.0% |
| Gastritis |
3.8% |
| Hypothyroidism |
3.2% |
| Mental Disorder |
3.2% |
| Pneumonia |
3.2% |
| Prophylaxis |
3.2% |
| Diabetes Mellitus |
2.2% |
| Ectopic Acth Syndrome |
2.2% |
| Nephrogenic Diabetes Insipidus |
2.2% |
| Infection |
1.1% |
| Neoplasm |
1.1% |
| Acth Stimulation Test |
0.5% |
| Acth-producing Pituitary Tumour |
0.5% |
| Adrenal Insufficiency |
0.5% |
| Anticoagulant Therapy |
0.5% |
|
| Myoclonus |
14.1% |
| Off Label Use |
14.1% |
| Fatigue |
12.5% |
| Alanine Aminotransferase Increased |
10.9% |
| Hepatitis Acute |
9.4% |
| Nausea |
4.7% |
| Vomiting |
4.7% |
| Drug Interaction Potentiation |
3.1% |
| Hepatitis |
3.1% |
| Mental Status Changes |
3.1% |
| Potentiating Drug Interaction |
3.1% |
| Septic Shock |
3.1% |
| Surgery |
3.1% |
| Aspartate Aminotransferase Increased |
1.6% |
| Headache |
1.6% |
| Hypercholesterolaemia |
1.6% |
| Hypertension |
1.6% |
| Incorrect Route Of Drug Administration |
1.6% |
| Liver Function Test Abnormal |
1.6% |
| Multi-organ Failure |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.6% |
| Hypertension |
14.7% |
| Pituitary-dependent Cushing's Syndrome |
10.3% |
| Cushing's Syndrome |
7.4% |
| Hypercorticoidism |
5.9% |
| Carcinoid Tumour |
4.4% |
| Haemochromatosis |
4.4% |
| Haemolytic Anaemia |
4.4% |
| Multiple Myeloma |
4.4% |
| Adrenocortical Carcinoma |
2.9% |
| Hypokalaemia |
2.9% |
| Hypomagnesaemia |
2.9% |
| Hypothyroidism |
2.9% |
| Neoplasm Malignant |
2.9% |
| Gastritis |
1.5% |
| Hepatitis B |
1.5% |
| Myelodysplastic Syndrome |
1.5% |
| Pain |
1.5% |
| Pulmonary Arterial Hypertension |
1.5% |
| Steroid Therapy |
1.5% |
|
| Mitral Valve Incompetence |
14.3% |
| Vomiting |
14.3% |
| Hypoglycaemia |
9.5% |
| Pulmonary Embolism |
9.5% |
| Therapeutic Embolisation |
9.5% |
| Cardiovascular Disorder |
4.8% |
| Dyspnoea |
4.8% |
| Hyperglycaemia |
4.8% |
| Mixed Liver Injury |
4.8% |
| Off Label Use |
4.8% |
| Renal Failure |
4.8% |
| Somnolence |
4.8% |
| Transaminases Increased |
4.8% |
| Urinary Retention |
4.8% |
|
